Почетна › Dijabetes tipa 2 › Оклахома
Kliničke studije za Dijabetes tipa 2 u državi Оклахома
13 studija za Dijabetes tipa 2 traži učesnike na lokacijama u državi Оклахома.
Gradovi u državi Оклахома
Zvanični tekst studije (na engleskom)
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Tekton Research Oklahoma City, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07754461EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Tekton Research Oklahoma City, Oklahoma City
- South Oklahoma Heart Research Group, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07064473A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07351058A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Central States Research, Tulsa
Тражи се учесникФаза 3
Узраст од 10 до 17 · Оба пола · Ажурирано 5. 11. 2026. · NCT07668336A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT06897475A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Norman
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07662109A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07662213A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Hightower Clinical, Oklahoma City
- Medical Research International, LLC, Oklahoma City
- Ascension St. John - Jane Phillips Medical Center, Tulsa
Тражи се учесникЗдраве особе су добродошле
Узраст 55 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06112418A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743450AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Lynn Institute of Norman, Norman
Тражи се учесникФаза 3
Узраст 45 и старији · Оба пола · Ажурирано 1. 9. 2026. · NCT07797335A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 3
Узраст од 10 до 17 · Оба пола · Ажурирано 7. 8. 2026. · NCT06739122DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
- The University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникОпсервациона студија
Узраст од 8 до 15 · Оба пола · Ажурирано 7. 5. 2026. · NCT06525259Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Lynn Health Science Institute - Oklahoma City, Oklahoma City
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 3. 2026. · NCT07282743Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.